Diagnostics dedicated to Precision Medicine.

Acobiom is involved in the development of innovative and non-invasive Diagnostics dedicated to Precision Medicine. Hence, the company already developed In Vitro Diagnostic Assays based on New Blood Biomarkers in order to predict response to specific treatment or to prognose clinical evolution of patients.

Due to its expertise in Next-Generation Sequencing (NGS) technologies, genomics, transcriptomics and bioinformatics, Acobiom is currently involved in several developments concerning Precision Medicine, Companion Diagnostics and patient stratification tests, which will enable stratifying or segmenting patients according to typical profiles or phenotypes.

Acobiom proposes to clinicians two RUO In Vitro Assays based on qRT-PCR technology :
> a Diagnostic to predict response to Gemcitabine (Gemzar) treatment in Metastatic Pancreatic Cancer and to prognose a 15-months survival,
> a Diagnostic to prognose a positive 4-year survival in Chronic MyeloMonocytic Leukemia,

Other several innovative healthcare solutions are currently under clinical development. They concern Cancer and Alzheimer’s disease treatments.

If you need more information, please contact our Business Development Department
(T: +33(0)467 419 748, Email: busdev@acobiom.com)